KIMS enters into agreement to manage Splendid Hospitals, Hyderabad
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Offers affordable, high-quality solutions for diabetes care
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Subscribe To Our Newsletter & Stay Updated